Roman R. Gonzenbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roman R. Gonzenbach has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Björn Zörner
Brain Research Institute, University of Zürich, Zürich, Switzerland
1 shared publicationEva Hochreutener
Brain Research Institute, University of Zürich, Zürich, Switzerland
1 shared publicationMartin E. Schwab
Brain Research Institute, University of Zürich, Zürich, Switzerland
1 shared publicationPascal Gasser
Brain Research Institute, University of Zürich, Zürich, Switzerland
1 shared publicationVolker Dietz
Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland
1 shared publication
Latest Publications
- 25 June 2010
- Published by Wiley in Annals of Neurology
- Vol. 68 (1) , 48-57
Nogo‐A antibodies and training reduce muscle spasms in spinal cord‐injured rats
Objective: Spinal cord injury (SCI) leads to permanent motor and sensory deficits due to the damage of ascending and descending fiber tracts. In addition, malfunctions such as neuropathic pain or muscle spasms develop in many patients, possibly caused by injury‐induced plastic changes of neuronal circuits above and below the lesion. New treatment strategies for spinal cord injury aim at enhancing plasticity and neurite growth, for example, by blocking the key neurite growth inhibitor Nogo‐A or its downstream effectors. It is therefore crucial to investigate potential effects of such treatments on malfunctions such as muscle spasms. In addition, locomotor training, now a standard therapeutic tool to improve walking ability in incomplete SCI subjects, can be expected to influence the rearrangement of spinal cord circuits and the development of muscle spasms and other malfunctions.Methods and Results: Here we present and validate a new rat model for muscle spasms after incomplete SCI and show that both intrathecal anti–Nogo‐A antibody treatment and locomotor training, started early after injury, permanently reduce the development of muscle spasms.Interpretation: The results show that an antibody‐mediated suppression of the growth inhibitory protein Nogo‐A leads to functional recovery and a lower level of malfunctions, suggesting the formation of functionally meaningful connections in the damaged spinal cord. Treadmill training early after SCI also has a beneficial effect. ANN NEUROL 2010;68:48–57
- 25 June 2010
- Published by Wiley in Annals of Neurology
- Vol. 68 (1) , 48-57
Nogo‐A antibodies and training reduce muscle spasms in spinal cord‐injured rats
Objective: Spinal cord injury (SCI) leads to permanent motor and sensory deficits due to the damage of ascending and descending fiber tracts. In addition, malfunctions such as neuropathic pain or muscle spasms develop in many patients, possibly caused by injury‐induced plastic changes of neuronal circuits above and below the lesion. New treatment strategies for spinal cord injury aim at enhancing plasticity and neurite growth, for example, by blocking the key neurite growth inhibitor Nogo‐A or its downstream effectors. It is therefore crucial to investigate potential effects of such treatments on malfunctions such as muscle spasms. In addition, locomotor training, now a standard therapeutic tool to improve walking ability in incomplete SCI subjects, can be expected to influence the rearrangement of spinal cord circuits and the development of muscle spasms and other malfunctions.Methods and Results: Here we present and validate a new rat model for muscle spasms after incomplete SCI and show that both intrathecal anti–Nogo‐A antibody treatment and locomotor training, started early after injury, permanently reduce the development of muscle spasms.Interpretation: The results show that an antibody‐mediated suppression of the growth inhibitory protein Nogo‐A leads to functional recovery and a lower level of malfunctions, suggesting the formation of functionally meaningful connections in the damaged spinal cord. Treadmill training early after SCI also has a beneficial effect. ANN NEUROL 2010;68:48–57